Protein tyrosine phosphatase inactivation by electrophilic tyrosine modification

Madeleine L. Ware, David M. Leace, Zihan Qu, Quentin Schaefer, Sagar D. Vaidya, Mikayla L. Horvath, Zhihong Li, Yunpeng Bai, Zhong-Yin Zhang and Ku-Lung Hsu

Chem. Sci., 2026, 17, 5163
DOI: 10.1039/D5SC07398G

Development of PROTACs targeting estrogen receptor: an emerging technique for combating endocrine resistance

Rouming Peng, Xin Liu, Chun-Chi Chen, Rey-Ting Guo and Jian Min

RSC Med. Chem., 2025, 16, 1023
DOI: 10.1039/D4MD00961D

Native mass spectrometry of complexes formed by molecular glues reveals stoichiometric rearrangement of E3 ligases

Cara Jackson and Rebecca Beveridge

Analyst, 2024, 149, 3178
DOI: 10.1039/D4AN00110A

Design, synthesis and evaluation of antiproliferative effects of ferritin-targeted degraders

Yi Ai, Changqi Wang, Jiayi Zhu and Hang Zhong

Org. Biomol. Chem., 2025, 23, 6417
DOI: 10.1039/D5OB00603A

Exploration of degrons and their ability to mediate targeted protein degradation

Timothy J. Harris Jr. and Darci J. Trader

RSC Med. Chem., 2025, 16, 1067
DOI: 10.1039/D4MD00787E

Green synthesis for diverse bioactive benzo-fused spiroindolines through DBU-catalysed post-Ugi double cyclization

Shuang Zhao, Mengxiao Chen, Wenlu Zhou, Dan Ni, Zhenghua Li, Shenyou Nie and Yi He

Chem. Commun., 2024, 60, 5455
DOI: 10.1039/D4CC00846D

Factors Influencing the Efficacy and Safety of Thalidomide in the Treatment of Transfusion-Dependent Thalassaemia

晓琳戴

ACM, 2023, 13, 17050
DOI: 10.12677/ACM.2023.13112388

A Glutathione S-Transferase Pi Molecular Glue Tethers Splicing Factors and Remodels Cell Metabolism

David M. Leace, Madeleine L. Ware, Olivia Murtagh, Hsiao-Kuei Tsai, Chin-Yuan Chang and Ku-Lung Hsu

J. Am. Chem. Soc., 2025, 147, 36170
DOI: 10.1021/jacs.5c06951

CRBN ligand expansion for hematopoietic prostaglandin D2 synthase (H-PGDS) targeting PROTAC design and their in vitro ADME profiles

Hinata Osawa, Takashi Kurohara, Takahito Ito, Norihito Shibata and Yosuke Demizu

Bioorganic & Medicinal Chemistry, 2023, 84, 117259
DOI: 10.1016/j.bmc.2023.117259

Implications of frequent hitter E3 ligases in targeted protein degradation screens

Xiaoyu Zhang, Gabriel M. Simon and Benjamin F. Cravatt

Nat Chem Biol, 2025, 21, 474
DOI: 10.1038/s41589-024-01821-z

DCAF13 inhibits the p53 signaling pathway by promoting p53 ubiquitination modification in lung adenocarcinoma

Shan Wei, Jing Xing, Jia Chen, Liping Chen, Jiapei Lv, Xiaofei Chen, Tang Li, Tao Yu, Huaying Wang, Kai Wang and Wanjun Yu

J Exp Clin Cancer Res, 2024, 43
DOI: 10.1186/s13046-023-02936-2

Discovery and Characterization of Novel IKZF1/3 Glue Degraders against Multiple Hematological Cancer Cell Lines

Ting Wei, Pengli Wei, Yalei Wang, Yaqiu Mao, Jian Yan, Xiaotong Hu, Zhenze Qi, Xu Cai, Changkai Jia, Zhiyuan Zhao, Bingkun Li, Min Qiao, Yaxin Zou, Tingting Yang, Shiyang Sun, Xuesong Feng, Pengyun Li, Hongzhou Shang and Zhibing Zheng

OR, 2025, 33, 2981
DOI: 10.32604/or.2025.065123

Molecular glues and PROTACs in targeted protein degradation: mechanisms, advances, and therapeutic potential

Omar Eladl

Biochemical Pharmacology, 2025, 242, 117297
DOI: 10.1016/j.bcp.2025.117297

The 17th EFMC Short Course on Medicinal Chemistry on Small Molecule Protein Degraders

Alessio Ciulli, Suzanne O'Connor, Chun‐Wa Chung, Ingo V. Hartung, Andrea Testa, Danette L. Daniels and Laura H. Heitman

ChemMedChem, 2023, 18
DOI: 10.1002/cmdc.202300464

Identification of PTPN22 as a potential genetic biomarker for abdominal aortic aneurysm

Peng Ruan, Lei Gao, Hui Jiang, Tianshu Chu, Jianjun Ge and Xiang Kong

Front. Cardiovasc. Med., 2022, 9
DOI: 10.3389/fcvm.2022.1061771

Bruton Tyrosine Kinase Degraders in B-Cell Malignancies

Tiana Huynh, Sonia Rodriguez-Rodriguez and Alexey V. Danilov

Molecular Cancer Therapeutics, 2024, 23, 619
DOI: 10.1158/1535-7163.MCT-23-0520

Thalidomide as a rescue protocol for treatment of multiple myeloma in dogs: preliminary data from a multicentre retrospective study

Stefano Ciccarelli, Chiara Leo, Chiara Perrone, Delia Franchini, Irene Bonazzi and Riccardo Finotello

Front. Vet. Sci., 2026, 12
DOI: 10.3389/fvets.2025.1695122

Potential of GSPT1 as a novel target for glioblastoma therapy

Takashi Sasayama, Takeshi Hamada, Kazuhiro Tanaka, Hiroaki Nagashima, Shunsuke Yamanishi and Takehiko Ueyama

Cell Death Dis, 2024, 15
DOI: 10.1038/s41419-024-06967-1

Perspectives on chick embryo models in developmental and reproductive toxicity screening

Biswajeet Acharya, Sandip Dey, Prafulla Kumar Sahu, Amulyaratna Behera, Bimalendu Chowdhury and Suchismeeta Behera

Reproductive Toxicology, 2024, 126, 108583
DOI: 10.1016/j.reprotox.2024.108583

Analysis of Ubiquitin-Conjugating Enzyme E2T (UBE2T) Protein Levels in the Bone Marrow Biopsy Specimens of Patients With Multiple Myeloma

Fei Wang, Na Yu and Rong Xia

Cureus, 2025
DOI: 10.7759/cureus.82571

Targeting CRBN With Thalidomide Suppresses Fibrosis After Glaucoma Drainage Surgery Through NF-κB Pathway Inhibition

Lijun Wang, Hongsong Li, Lei Xiong, Chao Sun and Jianming Wang

Invest. Ophthalmol. Vis. Sci., 2026, 67, 48
DOI: 10.1167/iovs.67.3.48

RETRACTED: The effect of enantiomers of thalidomide on colon cells-Raman spectroscopy studies

Monika Kopec, Agnieszka Krzeminska, Jakub Surmacki, Paweł Krzyczmonik and Beata Brożek-Płuska

Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2025, 341, 126423
DOI: 10.1016/j.saa.2025.126423

Hirocidins, Cytotoxic Metabolites from Streptomyces hiroshimensis, Induce Mitochondrion‐Mediated Apoptosis

Esther J. Han, Myungeun Jeong, Seoung Rak Lee, Erik J. Sorensen and Mohammad R. Seyedsayamdost

Angew Chem Int Ed, 2024, 63
DOI: 10.1002/anie.202405367

Unraveling the Engagement of Kinases to CRBN Through a Shared Structural Motif to Optimize PROTACs Efficacy

Serena Rosignoli, Sara Giordani, Maddalena Pacelli, Giulia Guarguaglini and Alessandro Paiardini

Biomolecules, 2025, 15, 206
DOI: 10.3390/biom15020206

TALIDOMIDA E TERATOGENICIDADE: REVISÃO SISTEMÁTICA DE EVIDÊNCIAS MOLECULARES PARA AVALIAÇÃO DE RISCOS NA ASSISTÊNCIA À GESTANTE

Thayná Dos Reis Rodrigues, Francisco Honeidy Carvalho Azevedo and Victoria Gomes da Silva

RECIMA21, 2025, 6, e6117047
DOI: 10.47820/recima21.v6i11.7047

Screening for molecular glues – Challenges and opportunities

Geoffrey A. Holdgate, Catherine Bardelle, Sophia K. Berry, Alice Lanne and Maria Emanuela Cuomo

SLAS Discovery, 2024, 29, 100136
DOI: 10.1016/j.slasd.2023.12.008

Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions

Rajamanikkam Kamaraj, Subhrojyoti Ghosh, Souvadra Das, Shinjini Sen, Priyanka Kumar, Madhurima Majumdar, Renesa Dasgupta, Sampurna Mukherjee, Shrimanti Das, Indrilla Ghose, Petr Pavek, Muruga Poopathi Raja Karuppiah, Anil A. Chuturgoon and Krishnan Anand

Bioconjugate Chem., 2024, 35, 1089
DOI: 10.1021/acs.bioconjchem.4c00253

Monoterpenoid fluorophthalimide IMiDs that lack human cereblon binding: synthesis and anti-proliferative, anti-angiogenic and anti-inflammatory activities

Weiming Luo, Kathleen M. Garchitorena, David Tweedie, Cindy H. Chau, Chirag N. Patel, Maxime A. Siegler, Neil Vargesson, Inho Hwang, Soyeon Kim, Dong Seok Kim, William D. Figg and Nigel H. Greig

Biochemical and Biophysical Research Communications, 2025, 779, 152428
DOI: 10.1016/j.bbrc.2025.152428

Synthesis of α-(azidomethyl)glutarimide and its applicationin construction of potential Cereblon ligands via the CuAAC reaction

Liliya R Khuzhakhmetova, Anna A Ananeva, Grigory P Kantin, Dmitry Viktorovich Dar’in, Alexander S Bunev, Sebastian Ebeling, Alexander Herrmann, Marcus D Hartmann, Stanislav A Kalinin and Olga Yu Bakulina

Mendeleev Communications, 2025, 35, 69
DOI: 10.71267/mencom.7543

Protein degradation: expanding the toolbox to restrain cancer drug resistance

Hui Ming, Bowen Li, Jingwen Jiang, Siyuan Qin, Edouard C. Nice, Weifeng He, Tingyuan Lang and Canhua Huang

J Hematol Oncol, 2023, 16
DOI: 10.1186/s13045-023-01398-5

Pan-cancer analysis reveals the prognostic and immunologic roles of cereblon and its significance for PROTAC design

Si-Han Zhang, Na Zeng, Jian-Xuan Sun, Chen-Qian Liu, Jin-Zhou Xu, Meng-Yao Xu, Ye An, Xing-Yu Zhong, Si-Yang Ma, Hao-Dong He, Qi-Dong Xia, Jia Hu and Shao-Gang Wang

Heliyon, 2023, 9, e16644
DOI: 10.1016/j.heliyon.2023.e16644

Rapamycin vs TORin-1 or Gleevec vs Nilotinib: Simple chemical evolution that converts PAK1-blockers to TOR-blockers or vice versa?

Hiroshi Maruta and Hong He

DD&T, 2024, 18, 134
DOI: 10.5582/ddt.2023.01097

Multi criterion decision making analysis of hematologic cancer drugs via topological indices and physicochemical properties

Lina Huang, Saba Hanif, Muhammad Kamran Siddiqui, Muhammad Faisal Hanif, Muhammad Farhan Hanif and Mohamed Abubakar Fiidow

Sci Rep, 2025, 15
DOI: 10.1038/s41598-025-23474-1

Lung-specific CRBN knockout attenuates influenza a virus-induced acute lung injury in mice: a potential therapeutic approach

Lifang Zhang, Qingchao Zhang, Jiahui Chang, Yunyi Zhou, Wei Wang, Xiliang Wang, Chengyu Jiang and Yanli Zhang

BMC Infect Dis, 2025, 25
DOI: 10.1186/s12879-025-10490-9

Carbene-Catalyzed Phthalide Ether Functionalization for Discovering Chiral Phytovirucide that Specifically Targets Viral Nia Protein to Inhibit Proliferation

Xiaoyi Wang, Weijia Yang, Shang Wu, Fangru Jin, Zhongjie Shen, Xiangyang Li, Yonggui Robin Chi, Baoan Song and Runjiang Song

Research, 2025, 8
DOI: 10.34133/research.0637

A Novel Paradigm for Targeting Challenging Targets: Advancing Technologies and Future Directions of Molecular Glue Degraders

Yifan Zhang, Linlin Li, Jiajia Xu, Chunchen Che, Jiaqing Jia, Haohao Lu, Qidong You and Xiaoli Xu

Molecules, 2026, 31, 459
DOI: 10.3390/molecules31030459

Polymer-Modified Carbon Nanotubes as Smart Carriers for Anticancer Drug Delivery: Insights from MD and DFT Calculations

Somayeh Hamsayegan, Heidar Raissi, Afsaneh Ghahari and Farzaneh Farzad

Langmuir, 2025, 41, 21957
DOI: 10.1021/acs.langmuir.5c01621

A New Generation of IMiDs as Treatments for Neuroinflammatory and Neurodegenerative Disorders

Katherine O. Kopp, Margaret E. Greer, Elliot J. Glotfelty, Shih-Chang Hsueh, David Tweedie, Dong Seok Kim, Marcella Reale, Neil Vargesson and Nigel H. Greig

Biomolecules, 2023, 13, 747
DOI: 10.3390/biom13050747

Anti-emetic effects of thalidomide: Evidence, mechanism of action, and future directions

Paul L.R. Andrews, Robin S.B. Williams and Gareth J. Sanger

Current Research in Pharmacology and Drug Discovery, 2022, 3, 100138
DOI: 10.1016/j.crphar.2022.100138

Identification and structural basis of C-terminal cyclic imides as natural degrons for cereblon

Christopher Heim, Anna-Katharina Spring, Sören Kirchgäßner, Dirk Schwarzer and Marcus D. Hartmann

Biochemical and Biophysical Research Communications, 2022, 637, 66
DOI: 10.1016/j.bbrc.2022.11.001

Cereblon neo-substrate binding mimics the recognition of the cyclic imide degron

Christopher Heim, Anna-Katharina Spring, Sören Kirchgäßner, Dirk Schwarzer and Marcus D. Hartmann

Biochemical and Biophysical Research Communications, 2023, 646, 30
DOI: 10.1016/j.bbrc.2023.01.051

Mechanism of degrader-targeted protein ubiquitinability

Charlotte Crowe, Mark A. Nakasone, Sarah Chandler, Conner Craigon, Gajanan Sathe, Michael H. Tatham, Nikolai Makukhin, Ronald T. Hay and Alessio Ciulli

Sci. Adv., 2024, 10
DOI: 10.1126/sciadv.ado6492

Molecular glue degrader for tumor treatment

Yuhan Hu, Yan Yan, Jiehao Wang, Jiangxue Hou and Quande Lin

Front. Oncol., 2024, 14
DOI: 10.3389/fonc.2024.1512666

Drugging the undruggable: Chemical and biological insights into molecular glues in the pipeline

Kamel Metwally, Galal Yahya and Nader E. Abo-Dya

European Journal of Medicinal Chemistry, 2025, 300, 118132
DOI: 10.1016/j.ejmech.2025.118132

High-Throughput Screening of EGFR/Ca2+ Signaling Modulators in Cardiac Hypertrophy Using a Tetrahedral DNA Nanostructure-Based hESC Platform

Ke-Jia Wu, Yan-Fa Dai, Zhi-Qiang Wang, Wen Sun, Ya-Nan Zhu, Fan Chen, Ling Shao, Yao-Ye Huang, Qi Chen, Xin Liu, Yan Li, Hui-Min David Wang and Ning Sun

Journal of Pharmaceutical Analysis, 2025, 101479
DOI: 10.1016/j.jpha.2025.101479

Lessons learned in linking PROTACs from discovery to the clinic

Andy Pike, Esther C. Y. Lee, Iacovos N. Michaelides, Markus Schade, Ankit Sharma, James S. Scott and Abhishek Srivastava

Nat Rev Chem, 2025, 10, 117
DOI: 10.1038/s41570-025-00784-6

UDP-glucose, cereblon-dependent proinsulin degrader

Jaeyong Cho, Atsushi Miyagawa, Kazuki Yamaguchi, Wakana Abe, Yoji Tsugawa, Hatsuo Yamamura and Takeshi Imai

Sci Rep, 2022, 12
DOI: 10.1038/s41598-022-18902-5

ProxiCapture reveals context-dependent CRBN interactome landscape of molecular glue degraders

Rubina Kazi, Henry J. Bailey, Jan Gerhartz, Varun Jayeshkumar Shah, Betül Toker, Julia Bein, Peter Wild, Radosław P. Nowak, Thorsten Mosler and Ivan Dikic

Disease and Therapeutics, 2026, 2, 100004
DOI: 10.1016/j.dist.2026.100004

Discovery of Novel Potent Triple IKZF1/2/3 Degraders for the Treatment of Hematological Cancers

Ting Wei, Shiyang Sun, Xiaotong Hu, Pengli Wei, Zhiya Fan, Jian Yan, Yalei Wang, Zhenze Qi, Changkai Jia, Yaqiu Mao, Tingting Yang, Xu Cai, Bingkun Li, Zhiyuan Zhao, Min Qiao, Yaxin Zou, Weijie Qin, Xuesong Feng, Hongzhou Shang, Pengyun Li, Zhibing Zheng and Song Li

J. Med. Chem., 2025, 68, 16237
DOI: 10.1021/acs.jmedchem.5c01086

Exploration of Hydrazide-Based HDAC8 PROTACs for the Treatment of Hematological Malignancies and Solid Tumors

Chunlong Zhao, Jianqiu Zhang, Hangyu Zhou, Rita Setroikromo, Gerrit J. Poelarends and Frank J. Dekker

J. Med. Chem., 2024, 67, 14016
DOI: 10.1021/acs.jmedchem.4c00836

Targeted protein degradation: current molecular targets, localization, and strategies

Dimanthi Pliatsika, Cindy Blatter and Rainer Riedl

Drug Discovery Today, 2024, 29, 104178
DOI: 10.1016/j.drudis.2024.104178

Influence of Cytokine-Related genetic variants in TNF, IL6, IL1β, and IFNγ genes in the thalidomide treatment for Erythema nodosum leprosum in a Brazilian population sample

Miriãn Ferrão Maciel-Fiuza, Renan Cesar Sbruzzi, Mariléa Furtado Feira, Perpétua do Socorro Silva Costa, Renan Rangel Bonamigo, Rodrigo Vettorato, Letícia Maria Eidt, Paulo Cezar de Moraes, Bibiana Sampaio de Oliveira Fam, Stela Maris de Jezus Castro, Maria Irismar da Silva Silveira and Fernanda Sales Luiz Vianna

Human Immunology, 2025, 86, 111260
DOI: 10.1016/j.humimm.2025.111260

A selective RPL15 PROTAC degrader enhances anti-PD-1 immunotherapy in a murine melanoma tumor model

Runa Takahashi, Kazuki Yamamoto, Hikaru Toya, Haruka Shoji, Kohei Kawanishi, Kyoka Momosaki, Miyuki Yabe, Ken Takashima, Ryuta Muromoto, Satoshi Ichikawa, Tadashi Matsuda and Yuichi Kitai

Oncogene, 2025, 44, 4846
DOI: 10.1038/s41388-025-03641-4

Two-Photon Photodegradation of E3 Ubiquitin Ligase Cereblon by a Ru(II) Complex: Inducing Ferroptosis in Cisplatin-Resistant Tumor Cells

Xinlin Lin, Mengsi Zheng, Kai Xiong, Fa Wang, Yu Chen, Liangnian Ji and Hui Chao

J. Med. Chem., 2024, 67, 8372
DOI: 10.1021/acs.jmedchem.4c00545

Aptamer-Based Targeted Protein Degradation

Yuan Liu, Xu Qian, Chunyan Ran, Longjie Li, Ting Fu, Dan Su, Sitao Xie and Weihong Tan

ACS Nano, 2023, 17, 6150
DOI: 10.1021/acsnano.2c10379

Single-Cell Sequencing Reveals Thalidomide-Induced Teratogenicity in Zebrafish via Endoplasmic Reticulum Stress and Dysregulated Angiogenic Signaling

Jingjing Zhao and Tao Song

Journal of Craniofacial Surgery, 2026, 37, 746
DOI: 10.1097/SCS.0000000000011570

Protein degraders - from thalidomide to new PROTACs

Takumi Ito

The Journal of Biochemistry, 2024, 175, 507
DOI: 10.1093/jb/mvad113

EFMC: Trends in Medicinal Chemistry and Chemical Biology

Yves P. Auberson, Paola B. Arimondo, Maria Duca, Sebastian Essig, Uwe Grether, Arne C. Rufer, Gianluca Sbardella, Ulrich Schopfer, Antoni Torrens, Mario van der Stelt, Boris Vauzeilles, Olalla Vázquez and Andrew X. Zhang

ChemBioChem, 2023, 24
DOI: 10.1002/cbic.202200690

Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges

Khalil Choucair, Hafsa Imtiaz, Md Hafiz Uddin, Misako Nagasaka, Mohammad Najeeb Al-Hallak, Philip A. Philip, Bassel El-Rayes, Boris C. Pasche and Asfar S. Azmi

Sig Transduct Target Ther, 2025, 10
DOI: 10.1038/s41392-025-02473-8

Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders

Alena Kroupova, Valentina A. Spiteri, Zoe J. Rutter, Hirotake Furihata, Darren Darren, Sarath Ramachandran, Sohini Chakraborti, Kevin Haubrich, Julie Pethe, Denzel Gonzales, Andre J. Wijaya, Maria Rodriguez-Rios, Manon Sturbaut, Dylan M. Lynch, William Farnaby, Mark A. Nakasone, David Zollman and Alessio Ciulli

Nat Commun, 2024, 15
DOI: 10.1038/s41467-024-52871-9

Expanding the druggable proteome strategies and innovations in targeted protein degradation

Ke Ma, Ting Liu, Wen-Bo Huan, Ke-Zheng Chen and Sheng-Lin Qiao

Nano Today, 2026, 67, 102945
DOI: 10.1016/j.nantod.2025.102945

Oligomeric Remodeling by Molecular Glues Revealed Using Native Mass Spectrometry and Mass Photometry

Xiaojing Huang, Hari Kamadurai, Piro Siuti, Ezaz Ahmed, Jack L. Bennett and William A. Donald

J. Am. Chem. Soc., 2023, 145, 14716
DOI: 10.1021/jacs.3c02655

Accommodating Statistical and Physics-Based Computational Protocols for Molecular Glue Model and Evaluation

Qixuan Xu, Wenlang Liu, Hao Liu and Zheng Zheng

J. Chem. Inf. Model., 2025, 65, 6166
DOI: 10.1021/acs.jcim.5c00387

Thalidomide-induced limb malformations: an update and reevaluation

Michael D. Collins and William J. Scott

Arch Toxicol, 2025, 99, 1643
DOI: 10.1007/s00204-024-03930-z

Anhydrous and Stereoretentive Fluoride-Enhanced Suzuki–Miyaura Coupling of Immunomodulatory Imide Drug Derivatives

William F. Tracy, Geraint H. M. Davies, Lauren N. Grant, Jacob M. Ganley, Jesus Moreno, Emily C. Cherney and Huw M. L. Davies

J. Org. Chem., 2024, 89, 4595
DOI: 10.1021/acs.joc.3c02873

Unlocking DCAFs To Catalyze Degrader Development: An Arena for Innovative Approaches

Qi Miao, Vilas D. Kadam, Ayan Mukherjee, Zhi Tan and Mingxing Teng

J. Med. Chem., 2023, 66, 13369
DOI: 10.1021/acs.jmedchem.3c01209

Perspectives for the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma

Sergei Vyacheslavovich Semochkin

Clinical Oncohematology, 2024, 16, 229
DOI: 10.21320/2500-2139-2023-16-3-229-241

IKZF1: An important target for the treatment of autoimmune diseases

Siyuan Bu, Cong Ye, Shaozhe Cai and Lingli Dong

Clinical Immunology, 2025, 279, 110544
DOI: 10.1016/j.clim.2025.110544

Cross‐Linking Profiling of Molecular Glue Degrader‐Induced E3 Ligase Interactome to Expand Target Space

Yali Xu, Wensi Zhao, Hui‐Jun Nie, Jiamin Wang, Jingjing Fu, Hao Hu, Zihao Liu, Shengna Tao, Mingya Zhang, Yubo Zhou, Jia Li, Minjia Tan and Xiao‐Hua Chen

Angewandte Chemie, 2025, 137
DOI: 10.1002/ange.202505053

PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives

Makenzie Vorderbruggen, Carlos A. Velázquez-Martínez, Amarnath Natarajan and Adam R. Karpf

IJMS, 2024, 25, 5067
DOI: 10.3390/ijms25105067

Renaissance of Phoenix Drug Thalidomide—New Insights into Practical Clinical Application and Optimization Strategies for Managing Adverse Effects in Digestive Diseases

Xiaxiao Yan, Ziqi Guo, Chengzhen Lyu, Rou Tang, Rutong Li, Hongwei Wang, Kai Song, Wangyang Chen, Kun He and Dong Wu

Pharmaceuticals, 2025, 18, 1689
DOI: 10.3390/ph18111689

Green-synthesized silver-thalidomide nanoconjugates from Calotropis procera with enhanced anti-inflammatory via phospholipase A2 inhibition

Affaf Sajjad, Rida Fatima, Xolmurotov Fozil, Xolmuratov Xolilla Sariyevich and Khalid Saleh

Results in Chemistry, 2026, 25, 103296
DOI: 10.1016/j.rechem.2026.103296

A double-edged sword of neo-substrate degradation in PROTACs

Zihan Song, Chengze Duan, Mingfei Wu, Zunyuan Wang, Youlu Pan, Chixiao Zhang, Wenhai Huang and Shenxin Zeng

European Journal of Medicinal Chemistry, 2026, 301, 118253
DOI: 10.1016/j.ejmech.2025.118253

Facilitating the development of molecular glues: Opportunities from serendipity and rational design

Weiqing Jiang, Yunhan Jiang, Youfu Luo, Wenliang Qiao and Tao Yang

European Journal of Medicinal Chemistry, 2024, 263, 115950
DOI: 10.1016/j.ejmech.2023.115950

Recent Advances in Targeted Protein Degradation Molecular Glues as Anticancer Drugs

Yulin Shen, Wen Wen, Luoyang Chen, Nan Zhang, Wei Cong and Honggang Hu

Clin Exp Pharma Physio, 2025, 52
DOI: 10.1111/1440-1681.70064

Strengthening Molecular Glues: Design Strategies for Improving Thalidomide Analogs as Cereblon Effectors and Anticancer Agents

Michael J Nutt and Scott G Stewart

Drug Discovery Today, 2024, 29, 104010
DOI: 10.1016/j.drudis.2024.104010

Recent advances in developing targeted protein degraders

Binbin Cheng, Hongqiao Li, Xiaopeng Peng, Jianjun Chen, Chuxiao Shao and Zhihua Kong

European Journal of Medicinal Chemistry, 2025, 284, 117212
DOI: 10.1016/j.ejmech.2024.117212

SE(3)-equivariant ternary complex prediction towards target protein degradation

Fanglei Xue, Meihan Zhang, Shuqi Li, Xinyu Gao, James A. Wohlschlegel, Wenbing Huang, Yi Yang and Weixian Deng

Nat Commun, 2025, 16
DOI: 10.1038/s41467-025-61272-5

Hirocidins, Cytotoxic Metabolites from Streptomyces hiroshimensis, Induce Mitochondrion‐Mediated Apoptosis

Esther J. Han, Myungeun Jeong, Seoung Rak Lee, Erik J. Sorensen and Mohammad R. Seyedsayamdost

Angewandte Chemie, 2024, 136
DOI: 10.1002/ange.202405367

Thalidomide Synergistically Regulates Cell Cycle and Endoplasmic Reticulum Stress to Alleviate RPE Oxidative Damage Through the E2F2‐FBXO5 Pathway

Jingya Zhu, Xinyue Yu, Chaojuan Wen, Youao Zhang, Xielan Kuang, Nan Sun, Shiyu Tang, Bing Xiao, Sainan Xiao, Xun Wang, Kaili Wu, Qingjiong Zhang and Huangxuan Shen

The FASEB Journal, 2026, 40
DOI: 10.1096/fj.202502444R

The design and synthesis of a novel α-alkynylated biotin scaffold for use in heterobifunctional molecular probes

Jack W. Annear, Michael J. Nutt, Gavin R. Flematti, Joseph Rosenbluh and Scott G. Stewart

Tetrahedron Letters, 2025, 168, 155692
DOI: 10.1016/j.tetlet.2025.155692

Life mimics art

Muthukumaran Venkatachalapathy and Craig M. Crews

Cell Res, 2023, 33, 267
DOI: 10.1038/s41422-022-00765-0

Drug Repurposing in Veterinary Oncology: Myth or Reality?

Stefano Ciccarelli, Chiara Perrone, Maria Alfonsa Cavalera and Antonio Giuliano

Veterinary Sciences, 2025, 12, 1067
DOI: 10.3390/vetsci12111067

Recent advances in PROTAC-based antiviral and antibacterial therapeutics

Can Zhou, Shiwei Yang, Jun Wang, Wei Pan, Hongliang Yao, Gang Li and Minhong Niu

Bioorganic Chemistry, 2025, 160, 108437
DOI: 10.1016/j.bioorg.2025.108437

Development of visible-light photocaged molecular glues (vc-MGs) for B-cell malignancies therapy with improved safety and pharmacokinetic profiles in vivo

Wei Yan, Naizhen Zhang, Xiao Liu, Qiyu He, Xucheng Lv, Jianghui Sun, Lili Zhuang, Yuexin Zou, Yajie Zhang, Yuhang Liang, Yanjie Wang, Siyuan Li and Yonghui Sun

Chinese Chemical Letters, 2026, 37, 112064
DOI: 10.1016/j.cclet.2025.112064

Targeted protein degradation: therapeutic potential and challenges of PROTACs and molecular glues

Sun Kim and Eui-Bae Jeung

J Biomed Transl Res, 2025, 26, 21
DOI: 10.12729/jbtr.2025.26.2.21

The rise of degrader drugs

Mingxing Teng and Nathanael S. Gray

Cell Chemical Biology, 2023, 30, 864
DOI: 10.1016/j.chembiol.2023.06.020

Discovery of a Natural Ent-Kaurene Diterpenoid Oridonin as an E3 Ligase Recruiter for PROTACs

Jie Huang, Xuekun Fu, Fang Qiu, Zhijian Liang, Chunhao Cao, Zhuqian Wang, Hongzhen Chen, Siran Yue, Duoli Xie, Yiying Liang, Aiping Lu and Chao Liang

J. Am. Chem. Soc., 2025, 147, 1920
DOI: 10.1021/jacs.4c14650

Simultaneous determination of thirteen related substances in lenalidomide API by a stability-indicating RP-HPLC method

Zhiling Cao, Maolong Huang, Luye Bi, Ling Zhang, Siyi Xia, Yuhan Sun, Yang Yu, Xudong Yu, Dahua Sh and Fan Xu

Journal of Pharmaceutical and Biomedical Analysis, 2025, 260, 116823
DOI: 10.1016/j.jpba.2025.116823

Visual fluorescence discovery of the potent photoswitchable hTYR inhibitor to improve treatment strategy for hyperpigmentation

Dingqiang Fu, Xilei Ai, Xiaoyan Li, Yu Huang and Bo Liu

Sensors and Actuators B: Chemical, 2026, 448, 138988
DOI: 10.1016/j.snb.2025.138988

Protein post-translational modifications in CAR-T cells: Novel strategies to amplify antitumor efficacy via epigenetic and metabolic circuitry

Jiayi Li, Huihui Sun, Wenying Li, Ningning Zhao, Zhigang Guo, Jiannan Chen and Jun Yu

Critical Reviews in Oncology/Hematology, 2025, 216, 104968
DOI: 10.1016/j.critrevonc.2025.104968

Rapid access to pyrrolo[3,4-c]quinoline-1,3-diones: An improved synthetic protocol using a precursor prepared by Pfitzinger reaction

Marina G. Dimitrijević, Goran A. Bogdanović, Snežana Trifunović and Milan D. Joksović

Tetrahedron, 2023, 132, 133236
DOI: 10.1016/j.tet.2022.133236

Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives

Bruno Almeida Costa, Tarek H. Mouhieddine, Ricardo J. Ortiz and Joshua Richter

Critical Reviews in Oncology/Hematology, 2023, 187, 104040
DOI: 10.1016/j.critrevonc.2023.104040

Selective Proteolysis of Activated Transcriptional Factor by NIR‐Responsive Palindromic DNA Thalidomide Conjugate Inhibits the Canonical Smad Pathway

Min Hou, Rui Guo, Tianyu Ren, Tao Wang, Jian‐Hui Jiang and Jianjun He

Small, 2023, 19
DOI: 10.1002/smll.202302525

Pomalidomide sensitizes lung cancer cells to TRAIL/CDDP-induced apoptosis via directly targeting electron transfer flavoprotein alpha subunit

Liangping Li, Zetian Huang, Yuying Huang, Yongkun Li, Xuesong Ma, Pingping Li, Wenqing Du, Hui Wang, Yufei Zhao, Shulan Zeng, Yan Peng and Guohai Zhang

Bioorganic Chemistry, 2024, 153, 107815
DOI: 10.1016/j.bioorg.2024.107815

Targeted protein degradation for cancer therapy

Matthias Hinterndorfer, Valentina A. Spiteri, Alessio Ciulli and Georg E. Winter

Nat Rev Cancer, 2025, 25, 493
DOI: 10.1038/s41568-025-00817-8

Thalidomide: History of Research and Perspectives for Its Medical Use (Review)

D. V. Kurkin, D. A. Bakupin, E. I. Morkovin, I. S. Krysanov, E. V. Makarova, A. P. Tsaplina, D. L. Klabukova, O. V. Ivanova, Yu. V. Gorbunova, M. A. Dzhavakhyan, V. I. Zvereva, Yu. A. Kolosov and K. Yu. Aleshnikova

Pharm Chem J, 2024, 58, 1001
DOI: 10.1007/s11094-024-03236-5

Chimeric degraders in neurodegenerative diseases: Challenges and future directions

Hanyuan Zheng, Kun Cui, Jian Mao, You Wan and Jie Zheng

Journal of Translational Internal Medicine, 2025, 13, 508
DOI: 10.1515/jtim-2025-0099

Scalable insect cell expression and purification screening applied to CRL4-DCAF substrate receptors

Angus D. Cowan, Stefan Jaekel and Alessio Ciulli

Protein Expression and Purification, 2026, 241, 106907
DOI: 10.1016/j.pep.2026.106907

GELİŞİMSEL TOKSİSİTE ÇALIŞMALARINDA CİVCİV EMBRİYO MODELİ

Muhammed Hasan Şirin and Ayhan Filazi

Veteriner Farmakoloji ve Toksikoloji Derneği Bülteni, 2025, 16, 43
DOI: 10.38137/vftd.1609269

ZIF-90-loaded DNAzyme-responsive PROTAC for the self-powered degradation of NF-κB

Min Hou, Liang Sun, Tianyu Ren, Mingda Li, Chao Hu, Rong Liu, Shuang Gu, Mingyan Jiang, Jian-Hui Jiang and Jianjun He

Sci. China Chem., 2025, 68, 687
DOI: 10.1007/s11426-024-2246-0

PEAKS activation by PROTAC EPIC-0726 potentiates temozolomide in glioblastoma via K63/K48 ubiquitination-dependent ERK/AKT suppression and p21 stabilization

Biao Hong, Dongyuan Su, Xiaoteng Cui, Jixing Zhao, Qixue Wang, Qi Zhan, Eryan Yang, Shixue Yang, Jiasheng Ju, Yanping Huang, Chunchao Cheng, Yaqing Ding, Hanyi Xu, Longtao Cui, Yilin Zhao, Xun Zhao, Siwen Liang, Yuhao Liu and Chunsheng Kang

Neuro-Oncology, 2025
DOI: 10.1093/neuonc/noaf253

Optimization of novel quinazolinone derivatives as CRBN E3 ligase modulators for enhanced degradative activity and metabolic stability

Peng Chen, Hongkang Peng, Chen Liu, Yuxiang Li, Tong Yang, Mohan Li, Chengxuan Hu, Shaojie Li, Zihao Deng, Zhen Wang and Linyi Liu

Bioorganic Chemistry, 2026, 175, 109816
DOI: 10.1016/j.bioorg.2026.109816

Proteomic approaches advancing targeted protein degradation

Gajanan Sathe and Gopal P. Sapkota

Trends in Pharmacological Sciences, 2023, 44, 786
DOI: 10.1016/j.tips.2023.08.007

Marine‐Derived Molecular Glue Degraders: A New Frontier in Targeted Protein Degradation for Treatment of Multi‐Factorial Diseases

Vajagathali Mohammed, B. Haridevamuthu, Kathiravan Muthu Kumaradoss, S. Karthick Raja Namasivayam and Jesu Arockiaraj

Biotech and App Biochem, 2026, 73, 871
DOI: 10.1002/bab.70055

Cereblon E3 ligase complex genes are expressed in tissues sensitive to thalidomide in chicken and zebrafish embryos but are unchanged following thalidomide exposure

Lucas Rosa Fraga, Jessica Reeves, Chris Mahony, Lynda Erskine and Neil Vargesson

Developmental Biology, 2025, 522, 156
DOI: 10.1016/j.ydbio.2025.03.014

A review of thalidomide and digestive system related diseases

Zhao Xi, Wang Jie, Zou Long and Shi Shasha

Front. Oncol., 2025, 15
DOI: 10.3389/fonc.2025.1543757

Expert clinical framework report: Management of adverse events related to novel therapies for relapsed/refractory multiple myeloma (RRMM)

Jill Lacey, Joanne Hewitt, Jennifer L. Daley-Morris, Judith James, Jonathan Stevens and Olivier Blaizel

Can Hematol Today, 2022
DOI: 10.58931/cht.2022.1S1130

Discovery of DCAF16 Binders for Targeted Protein Degradation

Miguel A. Campos, Isabella A. Riha, Chenlu Zhang, Chen Mozes, Karl A. Scheidt and Xiaoyu Zhang

ACS Chem. Biol., 2025, 20, 479
DOI: 10.1021/acschembio.4c00799

IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors

Yu Wang, Shunsuke Shimosaki, Emi Ikebe, Hidekatsu Iha, Jun-ichi Yamamoto, Nichole Fife, Tomonaga Ichikawa, Mitsuo Hori, Masao Ogata, Yoshiyuki Tsukamoto, Naoki Hijiya, Masatsugu Moriyama, Shotaro Hagiwara, Shuichi Kusano, Masumichi Saito, Kamruddin Ahmed, Akira Nishizono, Hiroshi Handa and Kazuhiro Morishita

Front. Oncol., 2024, 13
DOI: 10.3389/fonc.2023.1272528

Native mass spectrometry for proximity-inducing compounds: a new opportunity for studying chemical-induced protein modulation

Emanuele Fabbrizi, Francesco Fiorentino, Fabrizio Casano, Antonello Mai and Dante Rotili

Expert Opinion on Drug Discovery, 2025, 20, 643
DOI: 10.1080/17460441.2025.2486146

Synergistic targeting of the ARID2–MYC axis by pomalidomide and panobinostat overcomes intrinsic IMiD resistance in multiple myeloma

Junichi Yamamoto, Tomoko Asatsuma-Okumura, Takumi Ito, Yoshiko Iwai, Hiroshi Handa and Yuki Yamaguchi

Sci Rep, 2026, 16
DOI: 10.1038/s41598-026-37740-3

AZD7762 induces CRBN dependent BAG3 degradation through ubiquitin-proteasome pathway

Yanli Liao, Chao Yuan, Mi Huang, WenXia Si, Duanzhuo Li, Weibin Wu, Shifa Zhang, Runkun Wu, Yi Quan, Xin Yu and Shengjie Liao

Anti-Cancer Drugs, 2024, 35, 46
DOI: 10.1097/CAD.0000000000001532

Luciferase- and HaloTag-based reporter assays to measure small-molecule-induced degradation pathway in living cells

Martin P. Schwalm, Krishna Saxena, Susanne Müller and Stefan Knapp

Nat Protoc, 2024, 19, 2317
DOI: 10.1038/s41596-024-00979-z

Clues for glues: from serendipity to nature’s blueprints in degrader discovery

Zuzanna Kozicka

Essays in Biochemistry, 2025, 69, 379
DOI: 10.1042/EBC20253058

Recent advances in targeted degradation in the RAS pathway

Zhiming Ge, Zisheng Fan, Wei He, Guizhen Zhou, Yidi Zhou, Mingyue Zheng and Sulin Zhang

Future Medicinal Chemistry, 2025, 17, 693
DOI: 10.1080/17568919.2025.2476387

The cereblon-AMPK (AMP-activated protein kinase) axis in chondrocytes regulates the pathogenesis of osteoarthritis

Yeon Lee, Hyo-Eun Kim, Ji-Sun Kwak, Chul-Seung Park and Jang-Soo Chun

Osteoarthritis and Cartilage, 2024, 32, 1579
DOI: 10.1016/j.joca.2024.08.009

Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation

Pengyun Li, Xiaotong Hu, Zhiya Fan, Shiyang Sun, Qijie Ran, Ting Wei, Pengli Wei, Qiyu Jiang, Jian Yan, Ning Yang, Changkai Jia, Tingting Yang, Yaqiu Mao, Xu Cai, Tingting Xu, Zhiyuan Zhao, Xiaohong Qian, Weijie Qin, Xiaomei Zhuang, Feng Fan, Junhai Xiao, Zhibing Zheng and Song Li

J Hematol Oncol, 2024, 17
DOI: 10.1186/s13045-024-01592-z

Pooled endogenous protein tagging and recruitment for systematic profiling of protein function

Yevgeniy V. Serebrenik, Deepak Mani, Timothé Maujean, George M. Burslem and Ophir Shalem

Cell Genomics, 2024, 4, 100651
DOI: 10.1016/j.xgen.2024.100651

Copper‐Mediated C(sp2)‐S Coupling: a Strategy for the Preparation of S‐Aryl Dithiocarbamates

Piyushkumar Satani, Sudha Soliya, Bharatkumar Prajapati, Kuldeep Joshi, Subrata Dutta and Togati Naveen

Asian J Org Chem, 2025, 14
DOI: 10.1002/ajoc.202500419

An overview of GPX4-targeting TPDs for cancer therapy

Xiaojuan Yang, Liqiang Wu and Shaohong Xu

Bioorganic & Medicinal Chemistry, 2025, 118, 118046
DOI: 10.1016/j.bmc.2024.118046

UDP-Glucose: A Cereblon-Dependent Glucokinase Protein Degrader

Jaeyong Cho, Atsushi Miyagawa, Kazuki Yamaguchi, Wakana Abe, Yoji Tsugawa, Hatsuo Yamamura and Takeshi Imai

IJMS, 2022, 23, 9094
DOI: 10.3390/ijms23169094

Advancement of Targeted Protein Degradation Strategies As Therapeutics for Undruggable Disease Targets

Mayuri P Kannan, Sarojini Sreeraman, Chaitanya S Somala, Raja BS Kushwah, Saravanan K Mani, Vickram Sundaram and Anand Thirunavukarasou

Future Med. Chem., 2023, 15, 867
DOI: 10.4155/fmc-2023-0072

Cross‐Linking Profiling of Molecular Glue Degrader‐Induced E3 Ligase Interactome to Expand Target Space

Yali Xu, Wensi Zhao, Hui‐Jun Nie, Jiamin Wang, Jingjing Fu, Hao Hu, Zihao Liu, Shengna Tao, Mingya Zhang, Yubo Zhou, Jia Li, Minjia Tan and Xiao‐Hua Chen

Angew Chem Int Ed, 2025, 64
DOI: 10.1002/anie.202505053